Eagle Pharmaceuticals Announced A Type C Meeting With The FDA Agreeing On A Path Forward To Advance The Development Of EA-114 For Breast Cancer In Post-menopausal Women. Eagle Currently Anticipates Filing A New Drug Application For EA-114 In 2024
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals has announced a Type C meeting with the FDA to advance the development of EA-114 for breast cancer in post-menopausal women. The company anticipates filing a New Drug Application for EA-114 in 2024.
August 29, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eagle Pharmaceuticals' announcement of advancing the development of EA-114 for breast cancer could potentially boost investor confidence in the company's pipeline.
The announcement of a Type C meeting with the FDA indicates progress in the development of EA-114. This could potentially boost investor confidence in the company's pipeline and lead to a positive impact on the stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100